Standout Papers

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diab... 2012 2026 2016 2021 4.1k
  1. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (2018)
    Stephen D. Wiviott, Itamar Raz et al. New England Journal of Medicine
  2. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (2013)
    Benjamin M. Scirica, Deepak L. Bhatt et al. New England Journal of Medicine
  3. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2018)
    Thomas A. Zelniker, Stephen D. Wiviott et al. The Lancet
  4. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome (2012)
    Gregory G. Schwartz, Anders Olsson et al. New England Journal of Medicine
  5. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure (2020)
    Deepak L. Bhatt, Michael Szarek et al. New England Journal of Medicine
  6. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (2020)
    Kausik K. Ray, R. Scott Wright et al. New England Journal of Medicine
  7. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease (2020)
    Deepak L. Bhatt, Michael Szarek et al. New England Journal of Medicine
  8. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol (2017)
    Kausik K. Ray, Ulf Landmesser et al. New England Journal of Medicine
  9. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial (2013)
    William T. Cefalu, Lawrence A. Leiter et al. The Lancet
  10. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia (2020)
    Frederick J. Raal, David Kallend et al. New England Journal of Medicine
  11. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus (2019)
    Thomas A. Zelniker, Stephen D. Wiviott et al. Circulation
  12. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial (2017)
    Marc S. Sabatine, Lawrence A. Leiter et al. The Lancet Diabetes & Endocrinology
  13. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease (2019)
    Subodh Verma, C. David Mazer et al. Circulation
  14. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management (2019)
    Stephanie A. Amiel, Pablo Aschner et al. The Lancet Diabetes & Endocrinology
  15. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease (2019)
    Anne C. Goldberg, Lawrence A. Leiter et al. JAMA
  16. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus (2020)
    Thomas A. Zelniker, Marc P. Bonaca et al. Circulation
  17. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study (2018)
    Christie M. Ballantyne, Maciej Banach et al. Atherosclerosis
  18. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum (2017)
    William T. Cefalu, Sanjay Kaul et al. Diabetes Care
  19. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial (2023)
    Kausik K. Ray, Frank L.J. Visseren et al. The Lancet Diabetes & Endocrinology
  20. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis (2021)
    R. Scott Wright, Kausik K. Ray et al. Journal of the American College of Cardiology
  21. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials (2022)
    Kausik K. Ray, Frederick J. Raal et al. European Heart Journal

Immediate Impact

1 by Nobel laureates 3 from Science/Nature 159 standout
Sub-graph 1 of 15

Citing Papers

Durable and efficient gene silencing in vivo by hit-and-run epigenome editing
2024 StandoutNature
Diabetes mellitus—Progress and opportunities in the evolving epidemic
2024 Standout
43 intermediate papers

Works of Lawrence A. Leiter being referenced

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
2020 Standout
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
and 24 more

Author Peers

Author Last Decade Papers Cites
Lawrence A. Leiter 22573 13843 9257 535 38.1k
Marja‐Riitta Taskinen 23571 16228 8529 565 44.3k
Antonio M. Gotto 16038 26174 9831 588 48.9k
Ernst J. Schaefer 15912 15774 5034 377 34.6k
Neil R Poulter 15008 8727 4553 439 33.8k
Philip J. Barter 16133 20207 6873 379 35.4k
Jacques Genest 10316 15748 8507 704 39.5k
Rury R. Holman 28999 9037 10634 347 39.3k
Christoph Wanner 17206 11513 9233 706 44.5k
Henry N. Ginsberg 12327 12024 6671 323 29.0k
William H. Herman 18393 5383 6767 404 35.1k

All Works

Loading papers...

Rankless by CCL
2026